FMC reported $867 million in quarterly revenues in Q2 2026, a decline of 17% from the same quarter last year. FMC’s North American business experienced the sharpest decline in sales, from $321 million in Q2 2025 to $249 million this year, the company reported. Asia excluding India was the second largest decline, dropping from $159 million to $101 million in revenues. For crop chemicals that can mean trading down to a generic or reducing the number of applications,” Brondeau elaborated. Additionally, during the second quarter, FMC entered into a commercial agreement with ag supplier Corteva to manufacture rimisoxafen, which included a $200 million upfront payment.